This data is based on our advanced treatment registry which collects outcome information as patients are treated. In particular, it doesn’t generalize to all knee stem cell procedures (only Regenexx-SD).

Our biostatistician queried and analyzed functional and pain questionnaire data from our advanced registry.

The Regenexx® Procedures are the nation's most advanced non-surgical stem cell and blood platelet treatments for common injuries and degenerative joint conditions, such as osteoarthritis and avascular necrosis. These stem cell procedures utilize a patient’s own stem cells or blood platelets to help heal damaged tissues, tendons, ligaments, cartilage, spinal disc, or bone.

The red graph above shows a decrease in pain after Regenexx-SD treatment. The graph above illustrates the average pain scale report pretreatment and at various time point post treatment (range from 0, no pain to 10, worst pain).

Patients with available pain scores were 1482, 643, 833, 651, 417, 224, 116, 29 - at the sequential time points (starting at pretreatment and ending with 36 months post-treatment).

The blue graph to the right shows a increase in function observed after Regenexx-SD treatment. The average LEFS score is illustrated below from before to after the procedure at various time points. In this scale, higher scores equal more function.

Patients with available LEFS scores were 1286, 567, 735, 578, 390, 212, 109, 19 - at the sequential time points (starting at pretreatment and ending with 36 months post-treatment).

It should be noted that this dataset contains both Regenexx-SD and Regenexx-SD Plus cases.

**KNEE ARTHRITIS FALL 2015 DATA**

**WHAT WAS MEASURED?**

- Function & Pain Data

**THE LOWER EXTREMITY FUNCTION SCALE (STANDARDIZED FUNCTION QUESTIONNAIRE)**

**MEANS OF PAIN SCALE REPORTED BY PATIENTS**

<table>
<thead>
<tr>
<th>MONTHS</th>
<th>0</th>
<th>1</th>
<th>2</th>
<th>3</th>
<th>6</th>
<th>12</th>
<th>24</th>
<th>30</th>
</tr>
</thead>
<tbody>
<tr>
<td>PAIN PRE-TREAT</td>
<td>4.4</td>
<td>2.7</td>
<td>2.6</td>
<td>2.5</td>
<td>2.2</td>
<td>2.2</td>
<td>2.2</td>
<td>1.9</td>
</tr>
</tbody>
</table>

**LEFS MEANS REPORTED BY PATIENTS**

The blue graph to the right shows a increase in function observed after Regenexx-SD treatment. The average LEFS score is illustrated below from before to after the procedure at various time points. In this scale, higher scores equal more function.

Patients with available LEFS scores were 1286, 567, 735, 578, 390, 212, 109, 19 - at the sequential time points (starting at pretreatment and ending with 36 months post-treatment).

It should be noted that this dataset contains both Regenexx-SD and Regenexx-SD Plus cases.

**About This Data**

This data is based on our advanced treatment registry which collects outcome information as patients are treated. In particular, it doesn’t generalize to all knee stem cell procedures (only Regenexx-SD). Our biostatistician queried and analyzed functional and pain questionnaire data from our advanced registry.

**Caution!**

This is registry data, which is not the same as a controlled trial. This means it was collected as patients were treated.

The Regenexx® Procedures are the nation’s most advanced non-surgical stem cell and blood platelet treatments for common injuries and degenerative joint conditions, such as osteoarthritis and avascular necrosis.

These stem cell procedures utilize a patient’s own stem cells or blood platelets to help heal damaged tissues, tendons, ligaments, cartilage, spinal disc, or bone.

888-525-3005 | www.regenexx.com | info@regenexx.com